皇冠正规娱乐平台
 首页  学院概况  新闻中心  本科生  研究生教育  科学研究  招生就业  学院党建  学院工会  团学园地  校友之家 
最新消息 · 北京大学第一医院原党委书记、院长刘新民教授主讲辽大宋则行名家大讲堂    12-04      · 皇冠正规娱乐平台学子在我校首届心理委员技能大赛中喜获佳绩    11-28      · 我院开展“爱心助‘嘉’、健康同行”大学生社区实践活动暨嘉陵江社区实践基地挂牌仪式    11-23      · 我校比价采购公告(皇冠正规娱乐平台实验设备招标)    06-20
教授
 教授 
 副教授 
 讲师 
 教辅 
 
学院通知  
讲座预告:Role and cl... 05-18
讲座预告:单细胞数据... 05-18
2022-2023学年度第二学... 05-15
我校党委第二巡察... 04-03
 
学团园地
 
皇冠正规娱乐平台研究生荆锐在辽... 06-27
皇冠正规娱乐平台召开 2023级沈阳... 01-14
皇冠正规娱乐平台学子在我校... 11-28
我院开展“爱心助‘... 11-23
 
 
当前位置: 首页>>教师队伍>>教授>>正文
 
研究员 陈烨
2010-10-28 15:27  

 

 

陈烨  研究员(三级),博士生导师
邮箱:
sy-chenye@163.com

 

陈烨,1965年01月,皇冠正规娱乐平台研究员,博士生导师,我校药物研究院院长。兼任辽宁省小分子靶向药物研发工程研究中心主任(省发改委),辽宁省医药原料药制备专业技术创新中心主任(省科技厅),沈阳市小分子靶向药物研发重点实验室主任,辽宁省职工创新工作室主任,我校药物化学研究室主任,我校基于靶点的药物设计与研究实验室主任。我校药学学科学术(及学位)委员会委员,我校药物化学学科带头人;担任国家重点研发计划、国家科技创新领军人才、科技部、教育部、辽宁省、陕西省、山西省、甘肃省和沈阳市等科技项目审评专家。沈阳市高层次人才“领军人才”,我校知识分子联谊会会长,沈阳市知识分子联谊会常务理事。

科学研究:
   研究方向:(1)抗肿瘤药物、抗病原菌体微生物药物的研发;(2)药物给药系统及成药性研究。
   主要从事基于受体、酶结构为靶点的小分子新药研发,基于计算机辅助药物设计,以及小分子化合物与结构生物学、化学生物学方向相关的研究工作,研究小分子化合物与生物大分子相互作用机理等,包括小分子作用于肿瘤相关靶标BCR-ABL、c-KIT、PHB、EZH2、EGFR、c-Met、ALK的新药发现,进行抑制剂的设计合成等,以及抗肿瘤药物和抗病原体微生物的活性筛选、作用机制、毒理学、药动学和给药系统等成药性研究。
   承担国家重大科技专项子课题、国家自然科学基金、国家火炬计划、科技部创新基金、辽宁省应用基础研究计划、辽宁省服务地方项目、沈阳市重大科技成果专项等三十余项科研课题;主持或参与项目获得国家级新药证书及注册批件16个;获得中国产学研合作创新奖,辽宁省科技成果转化奖,辽宁省政府科学技术进步奖,辽宁省医药科技进步奖等十余项;在包括在Eur.J.Med.Chem、Bioorg Chem等学术期刊发表论文60余篇,申请发明专利60余项,授权38项,PCT国际专利1项。主要讲授《药物设计学》、《药品生产质量管理工程》和《方法学》等研究生及本科生课程。

发表论文:
1.Liu Ju,Gong Yilin,Shi Jiantao,Hao Xuechen,Wang Yang,Zhou Yunpeng,Hou Yunlei,Liu Yajing,Ding Shi,Chen Ye*. Design, synthesis and biological evaluation of novel  N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives
as potential c-Met kinase inhibitors[J].European Journal of Medicinal Chemistry,2020,194:112244.
2.Shi Ding, Ziye Gao , Ziqiang Hu, Rui Qi, Xiangshan Zheng , Xiaoyong Dong, Mingjuan Zhang, Jiwei Shen, Tian Long , Yan Zhu, Lu Tian, Wenshan Song, Ruoqing Liu , Ying Li, Jiahuan Sun, Wenwen Duand, Ju Liu, Ye Chen*. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors[J].European Journal of Medicinal Chemistry,238 (2022) 114492.
3.Liu Ju,Liu Fang,Li Zhen,Li Chunyan,Wu Shuang,Shen Jiwei,Wang Huan,Du Siyuan,Wei Hao,Hou Yunlei,Ding Shi,Chen Ye*.Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents[J].Bioorganic Chemistry,2022,120(120).
4.Ding Shi,Dong Xiaoyong,Gao Ziye,Zheng Xiangshan,Ji Jingchao,Zhang Mingjuan,Liu Fang,Wu Shuang,Li Min,Song Wenshan,Shen Jiwei,Duan Wenwen,Liu Ju,Chen Ye*. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFRL858R/T790M kinase inhibitors[J].Bioorganic Chemistry,2022,118(118).
5.Wang Zhen,Shi Jiantao,Zhu Xianglong,Zhao Wenwen,Gong Yilin,Hao Xuechen,Hou Yunlei,Liu Yajing,Ding Shi,Liu Ju,Chen Ye*.Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors[J].Bioorganic Chemistry,2020,105:104371.
6.Ju Liu,Mingjun Jiang,Shengnan Li,Shi Ding,Xinghua Zhao,Yang Wang,Ye Chen*. Construction of Gambogic Acid HPMA Copolymer Coupling Drug Systemand Study on Anti-tumor Activity[J].Current Drug Delivery,2022,19(4):491-507.
7.Jiaojiao Zhang,Ju Liu,Ming Wang,Shi Ding,Xinghua Zhao,Yang Wang,Ye Chen*,Yutong Liang.Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis[J].Current Drug Delivery,2021,18(3):357-368.
8.Jiaojiao Zhang,Ju Liu,Ming Wang,Shi Ding,Xinghua Zhao,Yang Wang,Ye Chen*,Yutong Liang.Study on the Slow-Release Mometasone Furoate Injection of PLGA for the Treatment of Knee Arthritis[J].Current Drug Delivery,2021,18(3):357-368.
9.Zijun Zhou,Yang Wang,Jun Li,Baichun Hu,Xiaolin Lin,Ye Chen*,Rui Wang,Ju Liu,Hongsheng Liu.Design, synthesis, and biological evaluation of Cyclobentinib (CB1107) as a potential anti-CML agent[J].Medicinal Chemistry Research,2018,27(8):1863-1875.
10.Liu Ju,Li Jiawei,Zhu Yan,Jing Rui,Ding Shi,Zhang Jifang,Zhao Leyan,Chen Ye*,Shen Jiwei.Advances in Drug Therapy for Gastrointestinal Stromal Tumour.[J].Current medicinal chemistry,
DOI: 10.2174/0929867330666230505163151
11.Liu Ju,Zhang Yadong,Zhu Yan,Tian Lu,Tang Mingrui,Shen Jiwei,Ding Shi,Chen Ye*.Research Progress on Small Molecules Inhibitors Targeting TRK Kinases.[J].Current medicinal chemistry,2023,30(10):1175-1192.
12.Wei Hao,Li Zhen,Liu Fang,Wang Yang,Ding Shi,Chen Ye*,Liu Ju.The Role of FTO in Tumors and It's Research Progress.[J].Current medicinal chemistry,2022,23(5):924-933.
13.Jiaojiao Zhang,Jie Li,Ju Liu,Shi Ding,Xinghua Zhao,Yang Wang,Ye Chen*,Yutong Liang.Advances in Drug Therapy for Systemic Lupus Erythematosus[J].Current Medicinal Chemistry,2021,28(6):1251-1268.
14.Liu J , Li J , Shi J T ,Ye Chen*et al.Synthesis and Biological Evaluation of Novel 4-Phenylaminobenzofuro [2,3-d]pyrimidine Derivatives[J].Journal of the Chemical Society of Pakistan, 2020,42(4):564-571.
15.Li Jun,Li Jie,Zhang Jiaojiao,Shi Jiantao,Ding Shi,Liu Yajing,Chen Ye*,Liu Ju.Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.[J].Anti-cancer agents in medicinal chemistry,2020,20(5):559-570.
16.Liu Ju,Shi Jian–Tao,Gong Yi Lin,Ding Shi,Chen Ye*.Synthesis, crystal and antiproliferative activity of 2-[2-(2-fluorobenzylidene) hydrazinyl]-4-(1-methyl-1 H -indol-3-yl)thieno[3,2-d]pyrimidine[J].Molecular Crystals and Liquid Crystals,2019,692(1):53-61.
17.Liu Ju,Shi Jiantao,Hao Xuechen,Liu Yutong,Ding Shi,Wang Yang,Chen Ye*.Synthesis of New Substituted 2-amino-4H-benzo[h]chromene-3-carbonitrile

 

关闭窗口
 
Baidu
sogou